Immunocore Limited recalled 7,572 vials of KIMMTRAK injection on June 10, 2025. The affected lots may not provide the intended therapeutic effect. Consumers and healthcare providers should stop using the product immediately.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact IMMUNOCORE, LLC or your healthcare provider for guidance. Notification method: N/A
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The KIMMTRAK injection is a 100 mcg/0.5 mL solution for intravenous infusion after dilution. It was sold under NDC 80446-0401-01, with specific lot numbers 3D009AA09, 3D009AA10, 3D009AA25, and 3D009AA02. The product is manufactured in Denmark and was distributed nationwide.
The recall was initiated due to the drug being subpotent, meaning it may not deliver the intended dosage or therapeutic effect. This classification falls under Class II, indicating a high hazard level.
No specific injuries or incidents have been reported related to this recall. However, the potential for inadequate treatment poses a significant risk to patients.
Consumers and healthcare providers must stop using KIMMTRAK immediately. Contact Immunocore, LLC or consult with your healthcare provider for further guidance.
For more information, contact Immunocore at the customer service number provided on their official website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.